Skip to main content
Rudolph Navari, MD, Oncology, Birmingham, AL, USA Health University Hospital

RudolphMNavariMD

Oncology Birmingham, AL

Professor, Medicine, Indiana University School of Medicine

Dr. Navari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Navari's full profile

Already have an account?

Summary

  • Dr. Rudolph Navari is an oncologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including St. Vincent Kokomo, Saint Joseph Health System, University of Alabama Hospital, and University of Alabama Hospital. He received his medical degree from Virginia Commonwealth University School of Medicine and has been in practice 40 years. He specializes in hematologic oncology.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 1981 - 1983
  • University of Alabama Medical Center
    University of Alabama Medical CenterResidency, Internal Medicine, 1977 - 1980
  • Virginia Commonwealth University School of Medicine
    Virginia Commonwealth University School of MedicineClass of 1977

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2023 - 2025
  • MO State Medical License
    MO State Medical License 2020 - 2025
  • IN State Medical License
    IN State Medical License 1998 - 2025
  • AL State Medical License
    AL State Medical License 1978 - 2024
  • MS State Medical License
    MS State Medical License 2016 - 2024
  • IL State Medical License
    IL State Medical License 1998 - 1999
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting—Reply  
    Charles L Loprinzi, Rudolph M Navari, JAMA Oncology
  • Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting  
    Rudolph M Navari, Costantine Albany, Charles L Loprinzi, JAMA Oncology

Lectures

  • Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC ≥ 4. 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020
  • Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020

Press Mentions

  • Helsinn Publishes Results from a Secondary Analysis of a Phase 3 Trial in Patients with CINV Helsinn Publishes Results from a Secondary Analysis of a Phase 3 Trial in Patients with CINV
    Helsinn Publishes Results from a Secondary Analysis of a Phase 3 Trial in Patients with CINV Helsinn Publishes Results from a Secondary Analysis of a Phase 3 Trial in Patients with CINVJanuary 4th, 2023
  • FDA Updates Highlighting the Latest Cancer Treatments
    FDA Updates Highlighting the Latest Cancer TreatmentsNovember 20th, 2019
  • Study Finds Guideline Adoption Slow for Antiemetic Prophylaxis in Patients Receiving Carboplatin
    Study Finds Guideline Adoption Slow for Antiemetic Prophylaxis in Patients Receiving CarboplatinNovember 2nd, 2018
  • Join now to see all

Hospital Affiliations